DSEK: the pros and cons


DSEK: the pros and cons

Descemet's stripping with endothelial keratoplasty provides significant advantages over penetrating keratoplasty (PK), according to a study published in the March 2006 issue of the Journal of Cataract & Refractive Surgery.

The Price Vision Group, under the direction of Francis Price Jr., MD and Marianne Price, PhD, analysed the outcomes of 200 consecutive DSEK procedures, performed by the same surgeon, in order to establish early challenges associated with the method, as well as techniques required to promote donor tissue adherence.

The technique involved stripping Descemet's membrane and endothelium from the recipient's central cornea and transplanting an 8.0 to 9.0 mm disc of donor endothelium and posterior stroma through a 5.0 mm incision, with sutures used simply to close the incision. Follow-up was seven to 20 months for 124 eyes and two to six months for 76 eyes.

At the study's conclusion, the investigators admitted that the most frequent challenge was inadequate donor attachments. Any incidences of donor detachment were remedied by injecting an air bubble to press the donor against the recipient cornea. While there were seven primary graft failures, only one occurred in the second lot of 100 cases, which primarily used microkeratome-dissected donor tissue. Other, very rare, complications included papillary block glaucoma, cataract development and aqueous misdirection. However, DSEK was performed successfully following LASIK.

The authors concluded that DSEK did indeed offer certain advantages over PK, including more rapid healing, predictable refractive outcomes and enhanced corneal strength and integrity. Though the study group admitted donor adherence was slightly trickier, the procedure itself was technically easier and hence should be less traumatic to anterior chamber structures.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.